HBIO
Harvard Bioscience·NASDAQ
--
--(--)
--
--(--)
0.67 / 10
Underperform
HBIO's fundamental analysis is subpar, scoring 0.7/10. Key weaknesses include a negative net profit margin (-85.73%) and low revenue growth (-9.72% YoY). Although the company's revenue-to-market value ratio is high (1.45), indicating potential scale, other factors like asset turnover (1.41) and cash flow efficiency do not compensate for the profitability shortfall. Historical back-tests show negative monthly returns for most fundamental groups, reinforcing the weak fundamental stance.
Analysis Checks(3/10)
Revenue-MV
Value1.45
Score3/3
Weight-47.83%
1M Return3.41%
Value1.45
Score3/3
Weight-47.83%
1M Return3.41%
Total operating revenue (YoY growth rate %)
Value-9.72
Score1/3
Weight26.21%
1M Return-2.56%
Value-9.72
Score1/3
Weight26.21%
1M Return-2.56%
Net income-Revenue
Value-0.17
Score1/3
Weight8.54%
1M Return-0.69%
Value-0.17
Score1/3
Weight8.54%
1M Return-0.69%
Current assets turnover ratio
Value1.41
Score1/3
Weight20.82%
1M Return-1.72%
Value1.41
Score1/3
Weight20.82%
1M Return-1.72%
Asset-MV
Value-0.50
Score0/3
Weight25.13%
1M Return-6.43%
Value-0.50
Score0/3
Weight25.13%
1M Return-6.43%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight19.13%
1M Return-1.63%
Value100.00
Score2/3
Weight19.13%
1M Return-1.63%
Net cash flow from operating activities / Operating revenue (%)
Value10.87
Score2/3
Weight-12.20%
1M Return0.98%
Value10.87
Score2/3
Weight-12.20%
1M Return0.98%
Net profit margin (%)
Value-85.73
Score1/3
Weight16.64%
1M Return-1.60%
Value-85.73
Score1/3
Weight16.64%
1M Return-1.60%
EBIT / Total operating revenue (%)
Value-82.18
Score1/3
Weight24.02%
1M Return-2.44%
Value-82.18
Score1/3
Weight24.02%
1M Return-2.44%
Net profit / Total operating revenue (%)
Value-85.73
Score1/3
Weight19.54%
1M Return-1.90%
Value-85.73
Score1/3
Weight19.54%
1M Return-1.90%
Revenue-MV
Value1.45
Score3/3
Weight-47.83%
1M Return3.41%
Value1.45
Score3/3
Weight-47.83%
1M Return3.41%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight19.13%
1M Return-1.63%
Value100.00
Score2/3
Weight19.13%
1M Return-1.63%
Total operating revenue (YoY growth rate %)
Value-9.72
Score1/3
Weight26.21%
1M Return-2.56%
Value-9.72
Score1/3
Weight26.21%
1M Return-2.56%
Net cash flow from operating activities / Operating revenue (%)
Value10.87
Score2/3
Weight-12.20%
1M Return0.98%
Value10.87
Score2/3
Weight-12.20%
1M Return0.98%
Net income-Revenue
Value-0.17
Score1/3
Weight8.54%
1M Return-0.69%
Value-0.17
Score1/3
Weight8.54%
1M Return-0.69%
Net profit margin (%)
Value-85.73
Score1/3
Weight16.64%
1M Return-1.60%
Value-85.73
Score1/3
Weight16.64%
1M Return-1.60%
Current assets turnover ratio
Value1.41
Score1/3
Weight20.82%
1M Return-1.72%
Value1.41
Score1/3
Weight20.82%
1M Return-1.72%
EBIT / Total operating revenue (%)
Value-82.18
Score1/3
Weight24.02%
1M Return-2.44%
Value-82.18
Score1/3
Weight24.02%
1M Return-2.44%
Asset-MV
Value-0.50
Score0/3
Weight25.13%
1M Return-6.43%
Value-0.50
Score0/3
Weight25.13%
1M Return-6.43%
Net profit / Total operating revenue (%)
Value-85.73
Score1/3
Weight19.54%
1M Return-1.90%
Value-85.73
Score1/3
Weight19.54%
1M Return-1.90%
Is HBIO undervalued or overvalued?
- HBIO scores 0.67/10 on fundamentals and holds a Premium valuation at present. Backed by its -139.14% ROE, -61.62% net margin, -0.39 P/E ratio, 1.57 P/B ratio, and -266.67% earnings growth, these metrics solidify its Underperform investment rating.
